Pharma Journalist -

Synaffix B.V., a Lonza company, and Sidewinder Therapeutics have entered into a multi-target licensing agreement aimed at developing first-in-class bispecific antibody-drug conjugate…
Read More...

Alessa Therapeutics has received Fast Track designation from the U.S. Food and Drug Administration for Enolen®, its lead investigational therapy for the treatment of low- to…
Read More...

Cellenkos Inc., a clinical-stage biotechnology company developing off-the-shelf regulatory T cell (Treg) therapies, has received Orphan Drug Designation from the U.S. Food and Drug…
Read More...

Santhera Pharmaceuticals has signed an exclusive licensing agreement with Nxera Pharma UK to develop, manufacture, and commercialize AGAMREE® (vamorolone) for the treatment of Duchenne…
Read More...

Eli Lilly and Company has reported positive topline results from its novel TOGETHER-PsA Phase 3b trial, demonstrating that the concomitant use of Taltz (ixekizumab) and Zepbound…
Read More...

Amgen has announced the acquisition of Dark Blue Therapeutics Ltd., a privately held biotechnology company based in the United Kingdom, in a deal valued at up to $840 million. The…
Read More...

Octapharma USA has received approval from the U.S. Food and Drug Administration for a new 2-gram presentation of Fibryga®, a human plasma-derived fibrinogen concentrate, expanding…
Read More...

GSK plc has reported positive results from two pivotal phase III clinical trials evaluating bepirovirsen, an investigational antisense oligonucleotide therapy for chronic hepatitis B…
Read More...

Takeda Pharmaceutical Company has entered into a global collaboration and license agreement with Halozyme Therapeutics to use Halozyme’s proprietary ENHANZE® drug delivery technology…
Read More...

Eli Lilly and Company has agreed to acquire Ventyx Biosciences in an all-cash transaction valued at approximately $1.2 billion, strengthening Lilly’s pipeline in inflammation-driven…
Read More...